#covishield in india

[humongousyouthdelusion]

Recent Posts

Independence Day of India: Why celebrate? History,Facts

Side Effects of Covishield Vaccine: What are the side effects of Covishield Vaccine, how harmful is Covishield Vaccine for people?https://khabaradda24x7.com/

[gofitnesspro]

How to keep yourself safer and protected from the new COVID-19 Variant XBB.1.5 of 2023?

New COVID-19 Variant XBB.1.5 What is XBB.1.5? The New COVID-19 variant XBB.1.5 was discovered for the first time in the US in New York in October 2022. It is a recombinant or hybrid virus subvariant, which means it consists of two strains, in this case, two descendants of the Omicron BA.2 sub lineage. The XBB.1.5 variation features a mutation that virologists think makes the virus more capable…

[reportwire]

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

SII stopped Covishield production in Dec 2021, says CEO Adar Poonawalla

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired. Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers…

[bodyrevivehub]

The Serum Institute of India's CEO announced that the company has enhanced its manufacturing capabilities to prepare for the launch of vaccines against diseases like malaria and dengue in the coming years. This was achieved by repurposing facilities previously used for COVID-19 vaccines. With the decrease in demand for COVID-19 vaccines, the company is now utilizing these facilities to manufacture its newer shots, which are expected to increase total production by two and a half billion doses. Serum Institute is known for producing AstraZeneca's COVID-19 vaccine under the brand name Covishield in India, as well as Novavax's protein-based COVID shots. The company made a significant investment of $2 billion during the peak of the global health crisis to enhance its production capacity. Currently, Serum sells approximately 1.5 billion vaccine doses annually, with a total production capacity of up to 4 billion doses. CEO Adar Poonawalla highlighted the importance of this increased capacity, stating that in the event of a future pandemic, India could be fully vaccinated within three to four months. The company is also in discussions with other countries and governments to utilize its facilities in the event of future outbreaks, although specific details were not disclosed. Serum Institute has the capacity to manufacture 100 million doses of its malaria vaccine and has already produced 25 million doses ahead of its launch in the coming months. Despite advancements in healthcare, malaria remains a significant public health concern, particularly in sub-Saharan Africa, where it claims the lives of more than half a million people, mainly young children, annually. Poonawalla emphasized that Serum Institute's focus is on exporting its vaccines, including the malaria shot, to other countries rather than entering into technology transfer deals. The company is also conducting trials for a single-dose dengue vaccine, which is another mosquito-borne disease. This vaccine, developed based on research by the US National Institutes of Health, is currently in early- to mid-stage trials in India, with late-stage trials expected to be completed within the next three years. While Serum Institute is making strides in dengue vaccine development, Japan's Takeda Pharmaceutical already offers a dengue shot in countries such as Indonesia, Thailand, Argentina, and Brazil, which are currently experiencing a shortage of vaccines. Other companies, including Indian Immunologicals, are also working on developing vaccines against dengue. https://bodyrevivehub.com/health-news/ind-covid-serum-institute-india-vaccines-malaria-dengue/?feed_id=658&_unique_id=66b47e6dea61b

[market-news-24]

Today's Current Affairs: AstraZeneca Covid Vaccine Linked To Rare Blood Clotting Disorder If you're keeping up with the latest news, you might have heard about the recent findings regarding the AstraZeneca Covid-19 vaccine. Researchers have discovered a rare but fatal blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT) linked to the vaccine. The vaccine, developed in collaboration with Oxford University, has been sold as Covishield in India and Vaxzevria in Europe. The discovery of VITT has raised concerns about the safety of the vaccine, with researchers identifying a dangerous blood autoantibody directed against a protein called platelet factor 4 (PF4) as the culprit. This new research has important implications for vaccine safety and development, as well as shedding light on the genetic risk factors associated with the disorder. AstraZeneca has acknowledged the rare side effect and has taken steps to address the issue, including withdrawing the vaccine from certain markets. Stay informed about the latest developments in today's current affairs to stay ahead of the curve. [ad_2] Download Latest Movies in HD Quality Downloading In 15 seconds Scroll Down to End of This Post const downloadBtn = document.getElementById('download-btn'); const timerBtn = document.getElementById('timer-btn'); const downloadLinkBtn = document.getElementById('download-link-btn'); downloadBtn.addEventListener('click', () => downloadBtn.style.display = 'none'; timerBtn.style.display = 'block'; let timeLeft = 15; const timerInterval = setInterval(() => if (timeLeft === 0) clearInterval(timerInterval); timerBtn.style.display = 'none'; downloadLinkBtn.style.display = 'inline-block'; // Add your download functionality here console.log('Download started!'); else timerBtn.textContent = `Downloading In $timeLeft seconds`; timeLeft--; , 1000); ); [ad_1] 1. What is the rare but fatal blood clotting disorder associated with AstraZeneca's Covid-19 vaccine? - A. Vaccine-induced thrombosis and thrombocytopenia - B. Vaccine-related allergic reaction - C. Vaccine-induced fever and fatigue - D. Vaccine-associated muscle pain Answer: A. Vaccine-induced thrombosis and thrombocytopenia 2. What is the name of AstraZeneca's Covid-19 vaccine in India? - A. Covaxin - B. Covishield - C. Comirnaty - D. Moderna Answer: B. Covishield 3. In a research published in the New England Journal of Medicine, what did international experts identify in the PF4 antibodies associated with blood clotting disorders? - A. Different molecular fingerprints - B. Common genetic risk factors - C. New antigen targets - D. Unique vaccine components Answer: B. Common genetic risk factors 4. What rare side effect has been linked to the AstraZeneca Covid vaccine, causing blood clots and low blood platelet count? - A. Thrombocytosis - B. Thrombosis - C. Thrombotic Thrombocytopenic Syndrome (TTS) - D. Thrombophlebitis Answer: C. Thrombotic Thrombocytopenic Syndrome (TTS) [ad_2] What is the AstraZeneca Covid-19 vaccine known as in India? The AstraZeneca's Covid-19 vaccine was named CoviShield in India. What is VITT and how is it related to the AstraZeneca vaccine? VITT stands for vaccine-induced immune thrombocytopenia and thrombosis, which is a rare but fatal blood clotting disorder. It has been found to be related to the adenovirus vector-based Oxford-AstraZeneca vaccine, sold as Covishield in India and Vaxzevria in Europe. What was found to be the reason for VITT in relation to the AstraZeneca vaccine? An unusually dangerous blood autoantibody directed against a protein termed platelet factor 4 (or PF4) was found to be the reason for VITT in relation to the AstraZeneca vaccine. What have researchers discovered in a new study regarding PF4 antibodies? Researchers in a new study have found that the PF4 antibodies in both adenovirus

infection-associated VITT and classic adenoviral vector VITT share identical molecular fingerprints or signatures. They also noted that the pathways of lethal antibody production in these disorders must be virtually identical and have similar genetic risk factors. What important clinical implications have researchers mentioned regarding their findings? Researchers have noted that the findings regarding VITT have important clinical implications for rare cases of blood clotting after adenovirus (a common cold) infections, as well as implications for vaccine development. Lessons learned from VITT can be applicable to these cases and can help improve vaccine safety. [ad_1] Download Movies Now Searching for Latest movies 20 seconds Sorry There is No Latest movies link found due to technical error. Please Try Again Later. function claimAirdrop() document.getElementById('claim-button').style.display = 'none'; document.getElementById('timer-container').style.display = 'block'; let countdownTimer = 20; const countdownInterval = setInterval(function() document.getElementById('countdown').textContent = countdownTimer; countdownTimer--; if (countdownTimer < 0) clearInterval(countdownInterval); document.getElementById('timer-container').style.display = 'none'; document.getElementById('sorry-button').style.display = 'block'; , 1000); [ad_2] Today's current affairs bring to light a concerning discovery regarding the AstraZeneca Covid-19 vaccine. Researchers have found that the vaccine may increase the risk of a rare but fatal blood clotting disorder known as vaccine-induced immune thrombocytopenia and thrombosis (VITT). This disorder, caused by an autoantibody targeting a protein called platelet factor 4 (PF4), has been linked to the adenovirus vector-based AstraZeneca vaccine, sold as Covishield in India and Vaxzevria in Europe. Further research has shown that the PF4 antibodies in VITT after adenovirus infection and in classic adenoviral vector-induced VITT share identical molecular fingerprints. This has led experts to believe that the pathways of lethal antibody production in these disorders are virtually identical. The implications of these findings extend to improving vaccine safety and understanding rare cases of blood clotting after adenovirus infections. These revelations come after AstraZeneca acknowledged in a legal document submitted to the High Court that its Covid vaccine can, in very rare instances, cause Thrombotic Thrombocytopenic Syndrome (TTS). This rare side effect has been associated with the deaths of at least 81 people in the UK, as well as a number of serious injuries. As a result, the company has voluntarily withdrawn the Marketing authorization of its Covid vaccine from Europe and other global markets. [ad_1]

[eclecticstarlightblogger]

AstraZeneca: Ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19

Η AstraZeneca ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19, συμπεριλαμβανομένης της έκδοσης Covishield που παράγεται από το Serum Institute of India, επικαλούμενη εμπορικούς λόγους και τη διαθεσιμότητα ενημερωμένων εμβολίων που στοχεύουν νέες παραλλαγές του ιού. Η απόφαση αυτή έρχεται, ωστόσο, μετά τις πρόσφατες αποκαλύψεις για την επίσημη παραδοχή της εταιρείας σε…

[thoughtfullyblogger]

AstraZeneca: Ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19

Η AstraZeneca ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19, συμπεριλαμβανομένης της έκδοσης Covishield που παράγεται από το Serum Institute of India, επικαλούμενη εμπορικούς λόγους και τη διαθεσιμότητα ενημερωμένων εμβολίων που στοχεύουν νέες παραλλαγές του ιού. Η απόφαση αυτή έρχεται, ωστόσο, μετά τις πρόσφατες αποκαλύψεις για την επίσημη παραδοχή της εταιρείας σε…

[greekblogs]

AstraZeneca: Ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19

Η AstraZeneca ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19, συμπεριλαμβανομένης της έκδοσης Covishield που παράγεται από το Serum Institute of India, επικαλούμενη εμπορικούς λόγους και τη διαθεσιμότητα ενημερωμένων εμβολίων που στοχεύουν νέες παραλλαγές του ιού. Η απόφαση αυτή έρχεται, ωστόσο, μετά τις πρόσφατες αποκαλύψεις για την επίσημη παραδοχή της εταιρείας σε…

[skandaladiaplokidiafthora]

AstraZeneca: Ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19

Η AstraZeneca ανακοίνωσε την παγκόσμια απόσυρση του εμβολίου της για τον COVID-19, συμπεριλαμβανομένης της έκδοσης Covishield που παράγεται από το Serum Institute of India, επικαλούμενη εμπορικούς λόγους και τη διαθεσιμότητα ενημερωμένων εμβολίων που στοχεύουν νέες παραλλαγές του ιού. Η απόφαση αυτή έρχεται, ωστόσο, μετά τις πρόσφατες αποκαλύψεις για την επίσημη παραδοχή της εταιρείας σε…

[decentralvaccine]

Astra Zeneca Admits It’s Covid 19 Virus Can Lead To Rare Blood Clots

UK pharmaceutical giant AstraZeneca has admitted that its Covid-19 vaccine can lead to a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS). This acknowledgment comes amidst legal action against the company alleging severe harm and deaths linked to the vaccine, as reported by The Telegraph. The vaccine, known as Covishield and widely used in India, was created through a partnership between AstraZeneca and Oxford University amid the pandemic. Covishield's production was carried out by the Serum Institute of India.

[cavenewstimes]

'Safety first', says Bharat Biotech amid AstraZeneca row

NEW DELHI: Bharat Biotech on Thursday assured Covaxin ‘s safety amid debate over Astrazeneca ‘s admission that its Covid-19 vaccine , sold as Covishield in India, could cause “rare’ side effects.The vaccine company posted a statement on X, mentioning that Covaxin was the sole Covid-19 vaccine in the government’s Covid-19 immunisation programme to have conducted efficacy trials in India. The…

[secretearthquakecheesecake]

‼️Braking news... National, International and on Social media.‼️ ⛑️💉🩺💊 AstraZeneca's Corona vaccine poses a risk of ❤️ Heart attack: British company admitted in court; 175 crore doses of Covishield made from this formula were administered in India...

#AstraZeneca #CovidVaccines #Covishield

dainik-b.in/SkQytw8XcJb

#Modi's Naya Bharat

[ramtracking]

AstraZeneca Makes Big U-Turn, Admits Covishield Can Cause Rare Side Effects [ Serum Institute Of India ]

AstraZeneca Makes Big U-Turn, Admits Covishield Can Cause Rare Side Effects [News Summary] British pharma giant AstraZeneca has admitted that its Covid vaccine can cause a rare side effect, The Telegraph (UK) has reported. A big update has emerged in connection with COVID vaccine and its rare side effects, which are being questioned by several health experts. AstraZeneca, in collaboration with…

[ednetconsultant]

Some Basic Requirements that you need to know before applying for a Canada Study Visa

Canada continues to attract lots of international students in 2024 as well. Lots of students want to go to Canada from India for further education. There are lots of things that any student needs to know before applying for a Canada study visa. But as a student, you can't gather that much information so it is advised to visit Study abroad consultants in Delhi for Canada. The consultants will guide you and help you at every step, not only this they will let you know all the requirements related to the Canada study visa. 

To get admission to Canada you must have excellent academic scores. The study permit will be issued at the time of the arrival in Canada. Know you want to know how Indian students can study in Canada and what are the important things any student needs to know. 

What do you understand by a Canada Study Permit?

This is a type of document that is issued by the Canadian immigration government authorities and serves as permission for international students to study in Canada. Any international student can't study in Canada without this permission. 

For to get your permit for Canada you need to carry some specific documents with you. while applying for a Canada visa there are lots of important things which need to be fulfilled. 

For Canada study visas students need to carry the letter of introduction with the other important documents as well. 

Some basic eligibility criteria for a study permit in Canada. 

You need to Qualify as a fully vaccinated Traveller. In Canada, there are some accepted vaccines such as AstraZeneca/COVISHIELD, Bharat Biotech Covaxin, etc.

you need to show or you should have specific documents to show that you have adequate funds to pay your tuition fees, living expenses, return transportation for yourself, etc.

you need to show proof of your clear background with no criminal record. The student should have a police verification certificate with them. 

you need to show your medical certificates as well that you don't have any major health problems. 

when you get your college acceptance letter only after that you can apply for a study permit in Canada. 

Apart from these, there are some valid documents which are required for the visa.

The first one is a valid passport. According to the Canadian government, your passport validity covers the intended stay In Canada. Suppose you are planning to travel to Canada for a year course in September 2022 then your passport should be valid until at least September 2024. 

Acceptance letter from college and university you are going to attend. 

All the proofs of funds.

Passport-size photographs.

Immigration Medical Examination Result

English Language Proficiency Exam score is very important. 

Statement of purpose and credit card. 

so if you are planning to study in Canada or Study in the USA consultants in Delhi, you need to consult Ednetconsultants for that. You will get proper guidance regarding your admission. 

[nandedlive]

Dengue vaccine | मोठी बातमी! आता डेंग्यूचा होणार अंत; वर्षभरात येणारं लस, सायरस पूनावाला यांची घोषणा

Dengue vaccine | भारतातील लस किंग सायरस पूनावाला यांनी एक मोठे विधान केले आहे ज्यात त्यांनी म्हटले आहे की ते एका वर्षात डेंग्यूवर बरा करणार आहेत. सिरम इन्स्टिट्यूटचे चेअरमन सायरस पूनावाला यांनी सांगितले की, वर्षभरात आम्ही डेंग्यू उपचार आणि डेंग्यूची लस (Dengue vaccine ) विकसित करू. आफ्रिकन देश आणि भारतात या नवीन लसीची खूप गरज आहे, जिथे लाखो लोकांना या आजाराची लागण होत आहे. Malaria vaccine Covishield च्या यशानंतर, SII जगात प्रथमच मलेरियाची लस लॉन्च करणार आहे. या लसीची आफ्रिकन देशांमध्ये आणि भारताच्या अंतर्गत भागातही नितांत गरज आहे, जिथे लाखो लोकांना या सामग्रीमुळे संसर्ग होत आहे. मोठ्या संख्येने स्त्रियांना संक्रमित करणाऱ्या रोगासाठी एक लस आहे, ही एक लस आहे जी गर्भाशयाला संक्रमित करते. Work started at SII Serum Institute of India एसआयआय सीरम इन्स्टिट्यूट ऑफ इंडियामध्ये काम सुरू सायरस पूनावाला यांनी पत्रकार परिषदेत डेंग्यूसंदर्भात मोठी घोषणा केली. पूनावाला यांनी डेंग्यूच्या लसीची नितांत गरज सांगितली. सिरम इन्स्टिट्यूट डेंग्यूच्या लसीवर दीर्घकाळापासून काम करत आहे. आफ्रिकन देशांव्यतिरिक्त, संपूर्ण आशिया आणि भारतात डेंग्यूमुळे बरेच लोक मरतात. अलीकडेच, सीरम इन्स्टिट्यूटच्या अहवालाने निष्कर्ष काढला की डेंग्यू लसीचा एकच डोस प्रौढांमध्ये सुरक्षित आणि चांगल्या प्रकारे सहन केला जातो. सिरम इन्स्टिट्यूटमध्ये डेंग्यूची लस तयार करण्यासाठी सतत चाचणी आणि काम केले जात आहे. There will be a vaccine for all four types या चारही प्रकारांसाठी लस असेल सिरम इन्स्टिट्यूट ऑफ इंडियाचे अध्यक्ष सायरस पूनावाला यांनी डेंग्यूची लस वर्षभरात आणण्याची घोषणा केली आहे. यामध्ये डेंग्यूच्या चारही प्रकारांवर उपचार केले जातील. सीरम इन्स्टिट्यूट लवकरच लस बाजारात आणण्याच्या प्रक्रियेकडे पावले टाकू शकते. देशात औषधाच्या प्रसारासाठी जलदगती मंजुरीसाठी विज्ञान आणि तंत्रज्ञान मंत्रालयाकडे अर्ज करण्यासारख्या गोष्टींचा यात समावेश आहे. सीरमने आपल्या तंत्रज्ञानाचा वापर करण्यासाठी यूएस स्थित बायोटेक्नॉलॉजी कंपनी (व्हिस्टेरा) सोबत सहकार्य केले आहे. जागतिक आरोग्य संघटनेच्या (WHO) आकडेवारीनुसार, दरवर्षी 10 ते 40 कोटी डेंग्यू तापाचे रुग्ण आढळतात Read the full article